LFCR logo

LIFECORE BIOMEDICAL INC

LFCRNASDAQ
πŸ† #3442 by market capEarnings Feb 5US Equity
$6.39β–Ό $0.12 (βˆ’1.84%)
After hours Β· at close
πŸ””
Track LFCR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.8%
7dβ–Ό 0.2%
14dβ–² 0.2%
30dβ–Ό 2.7%
ytdβ–Ό 22.2%
1yβ–Ό 9.7%
🏦Market Cap
$242M
Small Cap
πŸ“ˆRevenue Growth (YoY)
27.3%
High Growth
πŸ“ŠGross Margin
29.3%
Moderate
πŸ’΅FCF Margin
6.4%
Moderate
βš–οΈP/S Ratio
1.5x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$6.32 – $6.49
52-Week Range
$3.63 – $8.98
Volume (shares)
53,670
Avg Volume (shares)
β€”
Shares Outstanding
37.9M
Next Earnings
2027-02-05

Fundamentals Snapshot

Annual Revenue
$129M
Last Q Revenue
$34M
P/E Ratio
β€”
P/S Ratio
1.5x
EPS (TTM)
$-1.31
Dividend Yield
β€”
Dilution (1yr)
+8.9%
LFCR logo

LIFECORE BIOMEDICAL INC

LFCR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$129M
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
31.4%
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$1M
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$6M
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.4Mβ–² +8.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$119Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About LIFECORE BIOMEDICAL INC

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Hold
10 analysts
Strong Buy0
Buy0
Hold7
Sell1
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.